Financing brings total capital raised to $19 million to progress the pipeline in inherited neurological and other devastating diseases where conventional genetic medicines have not succeeded.
San Francisco, CA — March 9th, 2026 — Tacit Therapeutics, an RNA trans-splicing company developing programmable RNA repair medicines, today announced the closing of its Series A financing bringing the company’s total capital raised to $19 million.
The proceeds will enable Tacit to advance its lead programs in inherited neurological diseases and expand its pipeline into additional therapeutic areas.
The Series A financing was led by KdT Ventures, with participation from Civilization Ventures and Michigan Capital Network, and other new and existing investors. The new capital will support advancement of Tacit’s lead neurological programs toward IND-enabling studies, and the expansion to additional therapeutic areas.
“Bringing genetic medicines to millions of people who need them requires us to rethink how genes are repaired,” said David Nelles, Ph.D., Chief Executive Officer and Co-Founder of Tacit Therapeutics. “We are building RNA trans-splicing medicines that can address large patient populations while avoiding the safety issues that have held back the field. Our platform brings together RNA biology, high-throughput screening, and AI-driven design to engineer highly specific and efficient trans-splicing therapeutics. This financing allows us to move our inherited neurological disease programs toward the clinic and to expand into additional high-value indications where conventional genetic medicine has struggled.”
Tacit Therapeutics is pioneering a powerful RNA trans-splicing approach that can correct mutations across large segments of target RNAs. This opens a path to treat large, complex gene-mediated diseases that are difficult to address with conventional viral-vector gene therapy or DNA editors. By operating at the RNA level without introducing foreign enzymes or permanently altering DNA, Tacit has the potential to address both safety/immunogenicity concerns and the risk of unintended genomic edits.
“RNA trans-splicing provides a single parameter optimization framework to accelerate preclinical gene editing timelines that should, in theory, rival traditional biologics. Tacit removes confounding factors like promoters, protein editors, and other risky payload derivatives, given the approach is inherently cell-state, cell-type-specific and fully nucleic-acid mediated,” said Phil Grayeski, Managing Partner at KdT Ventures. “Tacit’s dedication and implementation to automation and AI-driven design addresses the underlying challenges in traditional gene editing strategies, which have held back broad application of genetic medicine. If you think the RNA trans-splicing story will follow a similar arduous path to CRISPR-related technologies, you are deeply missing the bigger picture.”
About Tacit Therapeutics
Tacit Therapeutics is an RNA trans-splicing company developing a new class of genetic medicines that repair mutated RNA transcripts. Tacit’s platform uses spliceosome-mediated RNA trans-splicing to replace mutant segments of pre-mRNA with therapeutic sequences, generating corrected transcripts while preserving native gene regulation and leaving the genome intact.
By combining RNA biology, computation, AI-driven design, and high-throughput screening, Tacit engineers programmable trans-splicing therapeutics designed for specificity and broad applicability. Focused initially on inherited neurological diseases and expanding into additional therapeutic areas, Tacit aims to deliver durable, programmable, and mutation-agnostic treatments for patients with genetic disorders that are not adequately addressed by existing gene therapy or RNA approaches.
Media & Investor Inquiries
David Nelles, PhD
CEO
Tacit Therapeutics
info@tacittx.com
